Talk to us.

Combination Therapy for Cancer

Intensity is pioneering a new field of cancer treatment – in situ immune activation. The Company’s drug approach, now in phase 2 testing, is to inject its novel high dispersing cytotoxic formulation directly into a patient’s malignant tumors.

The new method concentrates potent drugs in the tumors to kill the cancer following the injection. This method results in significantly less toxicity than traditional intravenous delivery, which harms healthy tissue, as 95% of the drug remains in the tumor.

The potential benefits range from greatly reduced drug side effects with tumor destruction to the initiation of a natural immune response against the cancer. Preclinical data show that Intensity’s products result in significantly greater tumor growth inhibition regression from baseline, tumor eradication, and increased survival rate compared to conventional IV-delivered chemotherapy or drugs given intratumorally without the Company’s technology. Tumors die in a manner that allows for the adaptive immune system to recognize the cancer, attack untreated tumors, and to potentially prevent cancer from spreading or returning.

Quick Facts for Investors

Location: Westport, CT
VCapital Invested: 2015
CEO: Lewis H. Bender
Founded: 2012
Founded By: Lewis H. Bender
Industry: Biotechnology

Our Take

We believe that Intensity is in a strong position to attract interest from several large potential acquirers, subject to successful ongoing phase 2 trials. Most notable are Intensity’s clinical collaboration agreements with Bristol Myers Squibb and Merck.

News and Updates

November 30, 2021
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December
November 12, 2021
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting
November 3, 2021
Intensity Therapeutics’ Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November
June 30, 2021
Intensity Therapeutics named “Innovator of the Month” by Connecticut senator
June 2, 2021
Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors
May 20, 2021
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
March 24, 2021
Intensity: Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer
January 11, 2021
VCapital CEO Len Batterson joins Larry Levy in Fireside Chat to kick off Cavendish Summit Series
November 11, 2020
Intensity Therapeutics Reports Favorable Data in Patients with Advanced Solid Tumors at SITC 2020
September 17, 2020
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study
September 14, 2020
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
September 13, 2020
Gilead Sciences to Acquire Immunomedics
May 13, 2020
Intensity Therapeutics: Killing Cancer Through Direct Injection
March 21, 2020
Bio Boss Interview with Lew Bender of Intensity Therapeutics